Champions Oncology Inc CSBR.OQ CSBR.O is expected to show a rise in quarterly revenue when it reports results on March 11 for the period ending January 31 2025
The Hackensack New Jersey-based company is expected to report a 7.6% increase in revenue to $12.932 million from $12.02 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Champions Oncology Inc is for a loss of 1 cent per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Champions Oncology Inc is $8.00, below its last closing price of $10.01.
This summary was machine generated March 7 at 20:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)